21 October 2022 – PLC congratulates ARS Pharmaceuticals on their recent announcement of FDA acceptance of the NDA for neffy® for the treatment of allergic reactions including anaphylaxis. PLC filed the NDA on ARS Pharmaceuticals’ behalf and has supported Regulatory filings and clinical oversight since the program’s inception.
ARS Pharmaceuticals announces FDA acceptance of NDA for neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (type I) including Anaphylaxis
